PL401676A1 - Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania - Google Patents
Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywaniaInfo
- Publication number
- PL401676A1 PL401676A1 PL401676A PL40167612A PL401676A1 PL 401676 A1 PL401676 A1 PL 401676A1 PL 401676 A PL401676 A PL 401676A PL 40167612 A PL40167612 A PL 40167612A PL 401676 A1 PL401676 A1 PL 401676A1
- Authority
- PL
- Poland
- Prior art keywords
- dosage form
- solid dosage
- cytisine
- production method
- micronized
- Prior art date
Links
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 title abstract 3
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 title abstract 3
- 229940027564 cytisine Drugs 0.000 title abstract 3
- 229930017327 cytisine Natural products 0.000 title abstract 3
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 title abstract 3
- 239000007909 solid dosage form Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 229920002261 Corn starch Polymers 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Przedmiotem wynalazku jest stała postać dawkowania zawierająca cytyzynę, substancje pomocnicze charakteryzująca się tym, że zawiera od 0,1% do 5% zmikronizowanej cytyzyny, przy czym wszystkie cząsteczki mają średnicę mniejszą od 10 µm, skrobię kukurydzianą w ilości od 40% do 60%, przy czym korzystnie 99,9% cząstek ma rozmiar od 5 µm do 25 µm, celulozę mikrokrystaliczną w ilości od 40% do 60%, przy czym korzystnie wielkość jej cząstek wynosi: 99% poniżej 38µm; stosunek wagowy substancji pomocniczych do czynnej wynosi od 1:19 do 1:999. Przedmiotem wynalazku jest też sposób otrzymywania twardej kapsułki.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401676A PL220354B1 (pl) | 2012-11-19 | 2012-11-19 | Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania |
| AU2013346363A AU2013346363B2 (en) | 2012-11-19 | 2013-11-19 | Solid dosage form comprising micronized cytisine |
| NZ708199A NZ708199A (en) | 2012-11-19 | 2013-11-19 | Solid dosage form comprising micronized cytisine |
| HUE13826599A HUE048912T2 (hu) | 2012-11-19 | 2013-11-19 | Mikronizált cisztint tartalmazó szilárd gyógyszerformák |
| RS20200483A RS60249B1 (sr) | 2012-11-19 | 2013-11-19 | Čvrsti dozni oblik koji sadrži mikronizovan citizin |
| HRP20200642TT HRP20200642T1 (hr) | 2012-11-19 | 2013-11-19 | Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin |
| PT138265996T PT2919761T (pt) | 2012-11-19 | 2013-11-19 | Forma de dosagem sólida compreendendo citisina micronizada |
| DK13826599.6T DK2919761T3 (da) | 2012-11-19 | 2013-11-19 | Fast doseringsform omfattende mikroniseret cytisin |
| PCT/IB2013/060230 WO2014076680A1 (en) | 2012-11-19 | 2013-11-19 | Solid dosage form comprising micronized cytisine |
| LTEP13826599.6T LT2919761T (lt) | 2012-11-19 | 2013-11-19 | Kieta vaisto forma, apimanti mikronizuotą citiziną |
| ES13826599T ES2793527T3 (es) | 2012-11-19 | 2013-11-19 | Forma de dosificación sólida que comprende citisina micronizada |
| US14/443,584 US9387172B2 (en) | 2012-11-19 | 2013-11-19 | Solid dosage form comprising micronized cytisine and its production method |
| EP13826599.6A EP2919761B1 (en) | 2012-11-19 | 2013-11-19 | Solid dosage form comprising micronized cytisine |
| SI201331712T SI2919761T1 (sl) | 2012-11-19 | 2013-11-19 | Trdna dozirna oblika, ki vsebuje mikroniziran citizin |
| CL2015001343A CL2015001343A1 (es) | 2012-11-19 | 2015-05-18 | Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion. |
| CY20201100355T CY1122947T1 (el) | 2012-11-19 | 2020-04-15 | Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401676A PL220354B1 (pl) | 2012-11-19 | 2012-11-19 | Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL401676A1 true PL401676A1 (pl) | 2014-05-26 |
| PL220354B1 PL220354B1 (pl) | 2015-10-30 |
Family
ID=50730669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401676A PL220354B1 (pl) | 2012-11-19 | 2012-11-19 | Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9387172B2 (pl) |
| EP (1) | EP2919761B1 (pl) |
| AU (1) | AU2013346363B2 (pl) |
| CL (1) | CL2015001343A1 (pl) |
| CY (1) | CY1122947T1 (pl) |
| DK (1) | DK2919761T3 (pl) |
| ES (1) | ES2793527T3 (pl) |
| HR (1) | HRP20200642T1 (pl) |
| HU (1) | HUE048912T2 (pl) |
| LT (1) | LT2919761T (pl) |
| NZ (1) | NZ708199A (pl) |
| PL (1) | PL220354B1 (pl) |
| PT (1) | PT2919761T (pl) |
| RS (1) | RS60249B1 (pl) |
| SI (1) | SI2919761T1 (pl) |
| WO (1) | WO2014076680A1 (pl) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2957280A1 (en) | 2014-06-18 | 2015-12-23 | Pharmacia Polonica Spolka z Ograniczona Odpowiedzialnoscia | Solid pharmaceutical composition of cytisine and process for preparation thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201602145D0 (en) | 2016-02-05 | 2016-03-23 | Achieve Pharma Uk Ltd | Salt |
| KR102848174B1 (ko) | 2017-07-24 | 2025-08-27 | 어치브 파마 유케이 리미티드 | 시티신 염 |
| EP3598968A1 (en) | 2018-07-23 | 2020-01-29 | Adamed Pharma S.A. | Solid pharmaceutical cytisine composition |
| BG67408B1 (bg) * | 2019-04-12 | 2022-01-17 | Софарма Ад | Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости |
| EP4002389A1 (en) | 2020-11-17 | 2022-05-25 | TRUMPF Medizin Systeme GmbH + Co. KG | Operating room control and communication system |
| PL444090A1 (pl) * | 2023-03-16 | 2024-09-23 | Uniwersytet Rzeszowski | Polimerowe kompozycje z cytyzyną oraz sposób ich wytwarzania |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG65536B1 (bg) | 2004-04-16 | 2008-11-28 | "Софарма" Ад | Лекарствена форма, съдържаща цитизин |
| US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
| ES2592882T3 (es) | 2008-10-14 | 2016-12-02 | Mcneil Ab | Forma de dosificación intra-oral de múltiples porciones y uso de la misma |
| EP2233134A1 (en) * | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
-
2012
- 2012-11-19 PL PL401676A patent/PL220354B1/pl unknown
-
2013
- 2013-11-19 DK DK13826599.6T patent/DK2919761T3/da active
- 2013-11-19 US US14/443,584 patent/US9387172B2/en active Active
- 2013-11-19 EP EP13826599.6A patent/EP2919761B1/en active Active
- 2013-11-19 SI SI201331712T patent/SI2919761T1/sl unknown
- 2013-11-19 RS RS20200483A patent/RS60249B1/sr unknown
- 2013-11-19 LT LTEP13826599.6T patent/LT2919761T/lt unknown
- 2013-11-19 HU HUE13826599A patent/HUE048912T2/hu unknown
- 2013-11-19 NZ NZ708199A patent/NZ708199A/en unknown
- 2013-11-19 PT PT138265996T patent/PT2919761T/pt unknown
- 2013-11-19 AU AU2013346363A patent/AU2013346363B2/en active Active
- 2013-11-19 WO PCT/IB2013/060230 patent/WO2014076680A1/en not_active Ceased
- 2013-11-19 HR HRP20200642TT patent/HRP20200642T1/hr unknown
- 2013-11-19 ES ES13826599T patent/ES2793527T3/es active Active
-
2015
- 2015-05-18 CL CL2015001343A patent/CL2015001343A1/es unknown
-
2020
- 2020-04-15 CY CY20201100355T patent/CY1122947T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2957280A1 (en) | 2014-06-18 | 2015-12-23 | Pharmacia Polonica Spolka z Ograniczona Odpowiedzialnoscia | Solid pharmaceutical composition of cytisine and process for preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2793527T3 (es) | 2020-11-16 |
| PL220354B1 (pl) | 2015-10-30 |
| HRP20200642T1 (hr) | 2020-09-04 |
| RS60249B1 (sr) | 2020-06-30 |
| AU2013346363A1 (en) | 2015-06-11 |
| US9387172B2 (en) | 2016-07-12 |
| WO2014076680A1 (en) | 2014-05-22 |
| HUE048912T2 (hu) | 2020-08-28 |
| EP2919761A1 (en) | 2015-09-23 |
| SI2919761T1 (sl) | 2020-08-31 |
| AU2013346363B2 (en) | 2018-08-09 |
| NZ708199A (en) | 2018-10-26 |
| DK2919761T3 (da) | 2020-11-02 |
| LT2919761T (lt) | 2020-05-25 |
| EP2919761B1 (en) | 2020-01-15 |
| CL2015001343A1 (es) | 2015-10-23 |
| CY1122947T1 (el) | 2021-10-29 |
| US20150342884A1 (en) | 2015-12-03 |
| PT2919761T (pt) | 2020-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL401676A1 (pl) | Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania | |
| EA201692388A1 (ru) | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы | |
| ZA202303338B (en) | Orodispersible dosage unit containing an estetrol component | |
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| NZ611467A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| WO2015016822A3 (en) | Solid dietary compositions for ruminants and methods of making and using the same | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| BR112015023629A2 (pt) | formulação de acetato de abiraterona | |
| JP2010132694A5 (pl) | ||
| CR20110367A (es) | Particulas en polvo recubiertas | |
| MX2018005384A (es) | Composiciones y metodos para fabricar microparticulas de proteina. | |
| WO2013093869A3 (en) | Gel-type cosmetic composition for making up and/or caring for the skin | |
| WO2013175221A3 (en) | Composition | |
| MX375936B (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| TW201129386A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
| WO2012053785A3 (ko) | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| MX359554B (es) | Microesferas cristalinas y proceso para fabricacion de las mismas. | |
| MX363699B (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
| TR201909836T4 (tr) | Sitisinin katı farmasötik bileşimi ve bunun hazırlanması için proses. | |
| TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
| EA033291B1 (ru) | Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии | |
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| GEP201706672B (en) | Dry powder inhaler compositions comprising long acting muscorinic antagonists | |
| JP2015129124A5 (pl) |